[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620273":3},{"organization":4,"outcomesModule":7,"designInfo":105,"detailedDescription":11,"studyPopulation":108,"armGroups":109,"interventions":115,"overallOfficials":121,"centralContacts":126,"locations":134,"responsibleParty":179,"collaborators":11,"id":181,"slug":182,"hasResults":183,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":11,"eligibilityCriteria":186,"healthyVolunteers":183,"sex":187,"minAge":188,"maxAge":11,"enrollmentInfo":189,"targetDuration":192,"studyType":193,"phases":11,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":137,"whyStopped":11,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":79,"otherOutcomes":11},[9,13,15,17,19,21,23,25,27,29,31,33,35,37,39,41,44,46,48,50,52,54,56,58,61,63,65,67,69,71,73,75,77],{"measure":10,"description":11,"timeFrame":12},"Participant age",null,"Baseline",{"measure":14,"description":11,"timeFrame":12},"Participant sex",{"measure":16,"description":11,"timeFrame":12},"Participant race",{"measure":18,"description":11,"timeFrame":12},"Participant weight",{"measure":20,"description":11,"timeFrame":12},"Participant height",{"measure":22,"description":11,"timeFrame":12},"Participant body mass index (BMI)",{"measure":24,"description":11,"timeFrame":12},"Participant smoking status",{"measure":26,"description":11,"timeFrame":12},"Participant drinking status",{"measure":28,"description":11,"timeFrame":12},"Family history of MDS or other hematopoietic cancers",{"measure":30,"description":11,"timeFrame":12},"Participant myelodysplastic syndromes diagnosis information",{"measure":32,"description":11,"timeFrame":12},"Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis",{"measure":34,"description":11,"timeFrame":12},"Participant comorbidities at diagnosis",{"measure":36,"description":11,"timeFrame":12},"Participant Charlson comorbidity index (CCI) score at diagnosis",{"measure":38,"description":11,"timeFrame":12},"Prior clinical diagnosis of other cancers",{"measure":40,"description":11,"timeFrame":12},"Prior clinical diagnosis of hematological diseases",{"measure":42,"description":11,"timeFrame":43},"Anemia status at diagnosis","Bseline",{"measure":45,"description":11,"timeFrame":12},"Thrombocytopenia status at diagnosis",{"measure":47,"description":11,"timeFrame":12},"Neutropenia status at diagnosis",{"measure":49,"description":11,"timeFrame":12},"Iron overload status at diagnosis",{"measure":51,"description":11,"timeFrame":12},"Red blood cell (RBC) transfusion dependence status at diagnosis",{"measure":53,"description":11,"timeFrame":12},"International Prognostic Scoring System (IPSS) score at diagnosis",{"measure":55,"description":11,"timeFrame":12},"Revised International Prognostic Scoring System (IPSS-R) score at diagnosis",{"measure":57,"description":11,"timeFrame":12},"Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis",{"measure":59,"description":11,"timeFrame":60},"Bone marrow aspirate results","Baseline and up to 2-years",{"measure":62,"description":11,"timeFrame":60},"Presence of dysplasia",{"measure":64,"description":11,"timeFrame":60},"Cytogenetic test results",{"measure":66,"description":11,"timeFrame":12},"Mutation test results at diagnosis",{"measure":68,"description":11,"timeFrame":12},"Complete blood count test results at diagnosis",{"measure":70,"description":11,"timeFrame":60},"Mean corpuscular volume (MCV)",{"measure":72,"description":11,"timeFrame":60},"C-reactive protein (CRP)",{"measure":74,"description":11,"timeFrame":60},"Serum ferritin (SF) level",{"measure":76,"description":11,"timeFrame":60},"Serum erythropoietin levels",{"measure":78,"description":11,"timeFrame":60},"Lactate dehydrogenase (LDH)",[80,82,84,87,89,91,93,95,97,99,101,103],{"measure":81,"description":11,"timeFrame":12},"Initial treatment received following diagnosis",{"measure":83,"description":11,"timeFrame":12},"Prior treatments and concomitant medications received",{"measure":85,"description":11,"timeFrame":86},"Subsequent treatments received","Up to 2-years",{"measure":88,"description":11,"timeFrame":12},"Time from diagnosis to treatment initiation",{"measure":90,"description":11,"timeFrame":86},"Treatment duration",{"measure":92,"description":11,"timeFrame":60},"Real-world overall survival (rwOS)",{"measure":94,"description":11,"timeFrame":60},"Time to disease-risk progression (per IPSS-R)",{"measure":96,"description":11,"timeFrame":60},"Time to acute myeloid leukemia (AML) progression",{"measure":98,"description":11,"timeFrame":60},"Time to iron overload",{"measure":100,"description":11,"timeFrame":60},"Overall response rate (ORR)",{"measure":102,"description":11,"timeFrame":60},"Duration of response (DOR)",{"measure":104,"description":11,"timeFrame":60},"Real-world relapse-free survival (rwRFS)",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":106,"timePerspective":107,"maskingInfo":11},"COHORT","OTHER","The registry will include adults who were\u002Fare newly diagnosed with myelodysplastic syndromes (MDS) in Asia (Singapore, South Korea and Taiwan).",[110],{"label":111,"type":11,"description":112,"interventionNames":113},"Group 1","Participants diagnosed with myelodysplastic syndromes (MDS)",[114],"Drug: Prescribed treatments for myelodysplastic syndromes (MDS)",[116],{"type":117,"name":118,"description":119,"armGroupLabels":120,"otherNames":11},"DRUG","Prescribed treatments for myelodysplastic syndromes (MDS)","According to the product label",[111],[122,125],{"name":123,"affiliation":5,"role":124},"Bristol Myers Squibb","STUDY_DIRECTOR",{"name":5,"affiliation":5,"role":124},[127,132],{"name":128,"role":129,"phone":130,"phoneExt":11,"email":131},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":133,"role":129,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[135,150,165],{"facility":136,"status":137,"city":138,"state":11,"zip":139,"country":138,"countryCode":140,"cosmosGeoPoint":141,"geoPoint":146,"contacts":147},"Singapore General Hospital","RECRUITING","Singapore","169608","SG",{"type":142,"coordinates":143},"Point",[144,145],103.85007,1.28967,{"lat":145,"lon":144},[148],{"name":149,"role":129,"phone":11,"phoneExt":11,"email":11},"Nurul Aidah, Site 0003",{"facility":151,"status":152,"city":153,"state":154,"zip":155,"country":156,"countryCode":11,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Local Institution - 002","NOT_YET_RECRUITING","Seoul","Seoul Teugbyeolsi","03080","South Korea",{"type":142,"coordinates":158},[159,160],126.9784,37.566,{"lat":160,"lon":159},[163],{"name":164,"role":129,"phone":11,"phoneExt":11,"email":11},"Site 002",{"facility":166,"status":152,"city":167,"state":11,"zip":168,"country":169,"countryCode":170,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Local Institution - 0001","Taipei","100229","Taiwan","TW",{"type":142,"coordinates":172},[173,174],121.52639,25.05306,{"lat":174,"lon":173},[177],{"name":178,"role":129,"phone":11,"phoneExt":11,"email":11},"Site 0001",{"type":180,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100620273","asia-myelodysplastic-syndrome-mds-registry-100620273",false,"NCT07355478","Asia Myelodysplastic Syndrome (MDS) Registry","Inclusion Criteria:\n\nRetrospective enrolment of Myelodysplastic Syndrome (MDS) participants:\n\n* Aged at least 18 years at initial diagnosis of MDS\n* Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and\n* Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate\n\nInclusion criteria for the prospective enrolment of MDS participants:\n\n* Aged at least 18 years at initial diagnosis of MDS; and\n* Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and\n* Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate\n\nExclusion Criteria:\n\n• None","ALL","18 Years",{"count":190,"type":191},500,"ESTIMATED","2 Years","OBSERVATIONAL","The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.",[196],"Myelodysplastic Syndromes (MDS)",[198],"Myelodysplastic syndromes (MDS)","2026-10-05",{"date":201,"type":202},"2026-10-08","ACTUAL",{"date":204,"type":202},"2026-08-11",{"date":206,"type":191},"2027-09-30",{"name":5,"class":6},3]